KRAS Mutation in Colon Cancer: A Marker of Resistance to EGFR-I Therapy[J] . Ahmad D. Siddiqui,Bilal Piperdi.Annals of Surgical Oncology . 2010 (4)Siddiqui AD and Piperdi B. KRAS mutation in colon cancer: a marker of resistance to EGFR-I therapy. Ann Surg Oncol 2010; 17: 1168-1176...
TheRASgene family is among the most studied and best characterized of the known cancer-related genes. Of the three human ras isoforms,KRASis the most frequently altered gene, with mutations occurring in 17%–25% of all cancers. In particular, approximately 30%–40% of colon cancers harbor a...
Additionally, testing for microsatellite instability and mismatch repair lends information for the option to use pembrolizumab, a PD-1 (programmed death 1) inhibitor. Pembrolizumab gained accelerated approval from the FDA in May 2017 for unresectable or metastatic colon cancer that has tested positive ...
Tumours located in the descending (C186) and sigmoid colon (C187) were classified as distal colon cancer, and tumours in the rectosigmoid junction (C199) and rectum (C209) were grouped together as rectal cancer. Stage at diagnosis was recorded according to SEER summary staging conventions (...
Predictive and prognostic roles of BRAF mutation in stage III colon cancer: results from intergroup trial CALGB 89803. Clin Cancer Res 2012;18:890-900... LB Saltz,RJ Mayer,P Schaefer,... - 《Clinical Cancer Research》 被引量: 393发表: 2012年 KRAS Mutation in Stage III Colon Cancer and...
unresectable or metastatic KRASG12C-mutated colorectal cancer (CRC). These findings, which are supported by pooled results from the Phase I/II KRYSTAL-1 trial, highlight the significance of testing and identifying KRASG12C mutations in CRC patients. The findings may also support a new standard...
Molecular biomarkers to determine the effectiveness of targeted therapies in cancer treatment have been widely adopted in colorectal cancer (CRC), but those to predict chemotherapy sensitivity remain poorly defined. We tested our hypothesis that KRAS mutation may be a predictor of oxaliplatin sensitivity...
withKRASwild-type tumors benefited from thetargeted therapy. At that time, John Marshall, MD, from the Lombardi Comprehensive Cancer Center, Georgetown University, in Washington, DC,commented,in hisMedscape Oncologyexpert blog, that theKRASdiscovery has effectively splitcolon cancerinto 2 separate ...
(mapaulo@ff. ulisboa.pt) KRAS oncogene repression in colon cancer cell lines by G-quadruplex binding indolo[3,2-c]quinolines João Lavrado1, Hugo Brito2, Pedro M. Borralho2, Stephan A. Ohnmacht3, Nam-Soon Kim4, Clara Leitão3, Sílvia Pisco3, Mekala Gunaratnam3, Cecília M. P. ...
◆All patients with metastatic colorectal cancer should have tumor tissue genotyped for RAS (KRAS and NRAS) and BRAF mutations individually or aspart of an NGS panel. 所有转移性结直肠癌患者都应对肿瘤组织进行RAS(KRAS和NR...